Effects of promyelocytic leukemia zinc finger (PLZF) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on U937 cell cycle
| Treatment . | Cell-cycle phase . | |||
|---|---|---|---|---|
| G1 . | S . | G2/M . | Sub G1 . | |
| None | 54.7 | 31.5 | 12.9 | 0.7 |
| PLZF | 71.7 | 15.3 | 10.8 | 2.3 |
| 1,25(OH)2D3 | 72.6 | 17.0 | 9.9 | 0.6 |
| PLZF and 1,25(OH)2D3 | 81.3 | 9.1 | 8.6 | 0.6 |
| Treatment . | Cell-cycle phase . | |||
|---|---|---|---|---|
| G1 . | S . | G2/M . | Sub G1 . | |
| None | 54.7 | 31.5 | 12.9 | 0.7 |
| PLZF | 71.7 | 15.3 | 10.8 | 2.3 |
| 1,25(OH)2D3 | 72.6 | 17.0 | 9.9 | 0.6 |
| PLZF and 1,25(OH)2D3 | 81.3 | 9.1 | 8.6 | 0.6 |
Values are the average percentage of cells in a given cell-cycle phase. At 48 hours after the beginning of the PLZF–1,25(OH)2D3–all-trans retinoic acid induction experiment, 2 × 105 cells were removed from each growth condition, fixed in ice-cold 70% ethanol, and resuspended in 10 μg/mL propidium iodide and 200 μg/mL ribonuclease A in phosphate-buffered saline. After a 30-minute incubation at 37°C, 1.5 × 103 cells for each condition were analyzed by flow cytometry.